Hyperoxia, HMGB1, and ventilator-associated pneumonia

American Journal of Respiratory Cell and Molecular Biology

Volumn 48, Issue 3, 2013, Pages 269-270

  Kennedy, Thomas P ^a   Nelson, Steve ^b,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LSU Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; HEPARIN; HEPARIN DERIVATIVE; HIGH MOBILITY GROUP B1 PROTEIN; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 4;

ACUTE LUNG INJURY; ARTERIAL OXYGEN TENSION; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; DEFENSE MECHANISM; EDITORIAL; FRACTION OF INSPIRED OXYGEN; HEALTH CARE COST; HUMAN; HYPEROXIA; INFLAMMATION; INNATE IMMUNITY; INTENSIVE CARE UNIT; LENGTH OF STAY; MACROPHAGE FUNCTION; NONHUMAN; OXYGEN CONCENTRATION; PATIENT POSITIONING; PHAGOCYTOSIS; PROGNOSIS; PROTEIN SECRETION; VENTILATED PATIENT; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; HMGB1 PROTEIN; HYPEROXIA; LUNG INJURY; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84874881247     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0020ED     Document Type: Editorial

References (23)

1. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
2. Centers for Medicare and Medicaid Services. Medicare program: proposed changes to the hospital inpatient prospective payment systems and fiscal year 2009 rates. Fed Regist 2008;73:23528.
3. Wip C, Napolitano L. Bundles to prevent ventilator-associated pneumonia: how valuable are theyCurr Opin Infect Dis 2009;22:159-166.
4. Zilberberg MD, Schorr AF. Ventilator-associated pneumonia as a model for approaching cost-effectiveness and infection prevention in the ICU. Curr Opin Infect Dis 2011;24:385-389.
5. Patel VS, Sitapara RA, Gore A, Phan B, Sharma L, Sampat V, Li J-H, Chavan SS, Wang H, Tracey KJ, Mantell LL. HMGB1 mediates hyperoxia-induced impairment of Pseudomonas aeruginosa clearance and inflammatory lung injury in mice. Am J Respir Cell Mol Biol 2013; 48:280-287.
6. O'Reilly PJ, Hickman-Davis JM, Davis IC, Matalon S. Hyperoxia impairs antibacterial function of macrophages through effects on actin. Am J Respir Cell Mol Biol 2003;28:443-450.
7. Morrow DM, Entezari-Zaher T, Romashko J III, Azghani AO, Javdan M, Ulloa L, Miller EJ. Mantell. Antioxidants preserve macrophage phagocytosis of Pseudomonas aeruginosa during hyperoxia. Free Radic Biol Med 2007;42:1338-1349.
8. Raffin TA, Simon LM, Braun D, Theodore J, Robin ED. Impairment of phagocytosis by moderate hyperoxia (40 to 60 percent oxygen) in lung macrophages. Lab Invest 1980;42:622-626.
9. Baleeiro CEO, Wilcoxen SE, Morris SB, Standiford TJ, Paine R III. Sublethal hyperoxia impairs pulmonary innate immunity. J Immunol 2003;171:955-963.
10. Nara C, Tateda K, Matsumoto T, Ohara A, Miyazaki S, Standiford TJ, Yamaguchi K. Legionella-induced acute lung injury in the setting of hyperoxia: protective role of tumour necrosis factor-a. J Med Microbiol 2004;53:727-733.
11. Kikuchi Y, Tateda K, Fuse ET, Matsumoto T, Gotoh N, Fukushima J, Takizawa H, Nagase T, Standiford TJ, Yamaguchi K. Hyperoxia exaggerates bacterial dissemination and lethality in Pseudomonas aeruginosa pneumonia. Pulm Pharmacol Ther 2009;22:333-339.
12. De Graaff AE, Dongelmans DA, Binnekade JM, de Jonge E. Clinicians' response to hyperoxia in ventilated patients in a Dutch ICU depends on the level of FiO2. Intensive Care Med 2011;37:46-51.
13. Andersson U, Tracey J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139-162.
14. Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J-H, Wang H, Yang H, Sharm L, Phan BD, et al. Inhibition of highmobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis. Mol Med 2012;18:477-485.
15. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, Xiap X. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 2007;81:741-747.
16. Dai S, Sodhi C, Cetin S, Richardson W, Branca M, Neal MD, Prindle T, Ma C, Shapiro RA, Li B, et al. Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of toll-like receptor-4 and increased cell-matrix adhesiveness. J Biol Chem 2010;285:4995-5002.
17. Van Zoelen MAD, Ishizaka A, Wolthuis EK, Choi G, van der Poll T, Schultz MJ. Pulmonary levels of high-mobility group box 1 during mechanical ventilation and ventilator-associated pneumonia. Shock 2008;29:441-445.
18. De Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PHJ, Bosman RJ, de Waal RAL, Wesselink R, de Keizer NF. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. Crit Care 2008;12:R156.
19. Rachmale S, Li G, Wilson G, Malinchoc M, Gajic O. Practice of excessive FIO2 and effect on pulmonary outcomes in mechanically ventilated patients with acute lung injury. Respir Care 2012;57: 1887-1893.
20. Lodato RF. Oxygen toxicity. In: Tobin MJ, editor. Principles and practice of mechanical ventilation. New York: McGraw-Hill; 2006. pp. 965-989.
21. Ling Y, Yang ZY, Yin T, Li L, Yuan WW, Wu HS, Wang CY. Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro. Int Immunopharmacol 2011;11:187-193.
22. Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, Prestwich GD, MacArthur RB, Walters BB, Hoidal JR, et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 2010;299: C97-C110.
23. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010;14:R180.